免疫抑制背景下HBV再激活的管理和预防

董凯惠; 方伊娜; 蒉乙文; 毛苗苗; 关艳儿; 温晓玉; 金清龙

doi:10.3969/j.issn.1001-5256.2018.10.033

免疫抑制背景下HBV再激活的管理和预防

DOI: 10.3969/j.issn.1001-5256.2018.10.033

吉林大学第一医院肝胆胰内科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2111
- HTML全文浏览量: 14
- PDF下载量: 427
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-08
- 出版日期: 2018-10-20

Management and prevention of HBV reactivation in the context of immunosuppression

Department of Hepatology, The First Hospital of Jilin University

摘要

摘要: 免疫抑制治疗期间HBV再激活的情况并不少见,这与肝炎爆发及肝功能失代偿引起的显著的发病率和死亡率有关,必须引起重视。然而,这种潜在并发症的预防和管理仍是临床医师工作中的难点。回顾了HBV再激活的诊断标准和临床结果,讨论了免疫抑制治疗如何影响HBV再激活的风险,并概述了预防HBV再激活的策略及最新进展。认为在免疫抑制治疗前对HBV感染者的早期识别至关重要,根据其风险分层,适时的启动抗病毒治疗可有效降低HBV再激活风险。希望借此提高临床医生对HBV再激活的认识,为优化HBV感染的管理和预防提供有效的参考。
- 肝炎病毒,乙型 /
- 病毒激活 /
- 免疫抑制剂 /
- 综述
Abstract: HBV reactivation is commonly seen during immunosuppressive therapy and is associated with high incidence and mortality rates due to hepatitis outbreak and liver decompensation, and therefore, it should be taken seriously. However, the prevention and management of this potential complication is still a difficulty in clinical practice. This article reviews the diagnostic criteria and clinical outcomes of HBV reactivation, discusses the association of immunosuppressive therapy with the risk of HBV reactivation, and outlines the strategies for the prevention of HBV reactivation and recent advances. It is pointed out that early identification of patients with HBV infection before immunosuppressive therapy is of vital importance, and the initiation of antiviral therapy at the right moment based on risk stratification can effectively reduce the risk of HBV reactivation. We hope that this review can increase the awareness of HBV reactivation among clinicians and provide an effective reference for optimizing the management and prevention of HBV infection.
- hepatitis B virus /
- virus activation /
- immunosuppressive agents /
- review

HTML全文

参考文献(37)

[1]OTT JJ, STEVENS GA, GROEGR J, et al.Global epidemiology of hepatitis B virus infection:New estimates of age-specific HBsAg seroprevalence and endemicity[J].Vaccine, 2012, 30 (12) :2212-2219.

[2]GBD 2013 Mortality and Causes of Death Collaborators.Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:A systematic analysis for the Global Burden of Disease Study 2013[J].Lancet, 2015, 385 (9963) :117-171.

[3]PATTULLO V.Hepatitis B reactivation in the setting of chemotherapy and immunosuppression-prevention is better than cure[J].World J Hepatol, 2015, 7 (7) :954-967.

[4]CHEUNG KS, SETO WK, LAI CL et al.Prevention and management of hepatitis B virus reactivation in cancer patients[J].Hepatol Int, 2016, 10 (3) :407-414.

[5]KUSUMOTO S, TANAKA Y, MIZOKAMI M, et al.Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma[J].Int J Hematol, 2009, 90 (1) :13-23.

[6]MOSES SE, LIM Z, ZUCKERMAN MA.Hepatitis B virus infection:pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients[J].Expert Rev Anti Infect Ther, 2011, 9 (10) :891-899.

[7]HWANG JP, Lok ASF.Management of patients with hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol, 2014, 11 (4) :209-219.

[8]CHOU CK, WANG LH, LIN HM, et al.Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells[J].Hepatology, 1992, 16 (1) :13-18.

[9]TAVAKOLPOUR S, ALAVIAN SM, SALI S.Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention:A comprehensive review[J].Hepat Mon, 2016, 16 (4) :e35810.

[10]KIM E, YUNE S, HA JM, et al.Hepatitis B virus reactivation during anti-cancer chemotherapy in patients with past hepatitis B virus infection[J].Hepatogastroenterology, 2014, 61 (134) :1704-1711.

[11]YEO W, ZEE B, ZHONG S, et al.Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J].Br J Cancer, 2004, 90 (7) :1306-1311.

[12]COLUCCIO C, BEGINI P, MARZANO A, et al.Hepatitis B in patients with hematological diseases:An update[J].World J Hepatol, 2017, 9 (25) :1043-1053.

[13]PERRILLO RP, GISH R, FALCK-YTTER YT.American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology, 2015, 148 (1) :221-244.

[14]CHEUNG KS, SETO WK, LAI CL, et al.Prevention and management of hepatitis B virus reactivation in cancer patients[J].Hepatology Int, 2016, 10 (3) :407-414.

[15]SHIH CA, CHEN WC, YU HC, et al.Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis[J].PLo SOne, 2015, 18:e0132426.

[16]KIM SJ, HSU C, SONG YQ, et al.Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab:Analysis from the Asia Lymphoma Study Group[J].Eur J Cancer, 2013, 49 (16) :3486-3496.

[17]DI BA, LOK, AS, MARTIN P, et al.Recent US Food and Drug Administration warnings on hepatitis B reactivation with immunesuppressing and anticancer drugs:Just the tip of the iceberg?[J].Hepatology, 2015, 61 (2) :703-711.

[18]SHIBOLET O, ILAN Y, GILLIN S, et al.Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers[J].Blood, 2002, 100 (2) :391-396.

[19]HWANG JP, FISCH MJ, ZHANG H, et al.Low rates of hepatitis B virus screening at the onset of chemotherapy[J].J Oncol Pract, 2012, 8 (4) :32-39.

[20]WEINBAUM CM, WILLIAMS I, MAST EE, et al.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[J].Hepatology, 2009, 49 (5 Suppl) :s35-s44.

[21]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[22]LIAW YF, LEUNG N, KAQ JH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:A 2008 update[J].Hepatol Int, 2008, 2 (3) :263-283.

[23]LOK AS, MCMAHON BJ.Chronic hepatitis B:Update 2009[J].Hepatology, 2009, 50 (3) :661-662.

[24]ARTZ AS, SOMERFIELD MR, Feld JJ, et al.American society of clinical oncology provisional clinical opinion:Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases[J].J Clin Oncol, 2010, 28 (19) :3199-3202.

[25]HAY AE, MEYER RM.Hepatitis B, rituximab, screening, and prophylaxis:Effectiveness and cost effectiveness[J].J Clin Oncol, 2012, 30 (26) :3155-3157.

[26]Expert Committee for Antiviral Therapy for Special Patients with Chronic Hepatitis B.Expert consensus on antiviral therapy for special patients with chronic hepatitis B:An update in 2015[J].JClin Hepatol, 2015, 31 (8) :1185-1192. (in Chinese) 慢性乙型肝炎特殊患者抗病毒治疗专家委员会.慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新[J].临床肝胆病杂志, 2015, 31 (8) :1185-1192.

[27]YUEN MF.Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy[J].Hepatol Int, 2016, 10 (1) :102-105.

[28]MA J, QI SK, MIAO XH, et al.Consensus of Chinese experts on HBV reactivation prevention and treatment for lymphoma immunotherapy[J].Chin Clin Oncol, 2013, 18 (10) :935-942. (in Chinese) 马军, 秦叔逵, 缪晓辉, 等.淋巴瘤免疫化疗HBV再激活预防和治疗中国专家共识[J].临床肿瘤学杂志, 2013, 18 (10) :935-942.

[29]SETO WK.Hepatitis B virus reactivation during immunosuppressive therapy:Appropriate risk stratification[J].World J Hepatol, 2015, 7 (6) :825-830.

[30]YOO JJ, CHO EJ, CHO YY, et al.Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation[J].Liver Int, 2015, 35 (12) :2530-2536.

[31]LOOMBA R, ROWLEY A, WESLEY R, et al.Systematic review:The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J].Ann Intern Med, 2008, 148 (7) :519-528.

[32]LOK AS, LAI CL, LEUNG N, et al.Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J].Gastroenterology, 2003, 125 (6) :1714-1722.

[33]LI P, XU H, DING HG.An except of Italian consensus guidelines for the recommendations for screening, monitoring, prevention, prophylax is and therapy of hepatitis B virus reactivation in patients with haematological malignancies and patients who underwent haematological stem cell transplantation a position paper (2017) [J].J Clin Hepatol, 2017, 33 (11) :2087-2090. (in Chinese) 李鹏, 徐辉, 丁惠国.《2017年意大利共识指南:血液系统恶性肿瘤以及接受造血干细胞移植患者HBV再激活的筛查、监测、预防和预防性治疗的建议》摘译[J].临床肝胆病杂志, 2017, 33 (11) :2087-2090.

[34]ZHANG MY, ZHU GQ, SHI KQ, et al.Systematic review with network meta-analysis:Comparative efficacy of oral nucleos (t) ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation[J].Oncotarget, 2016, 7 (21) :30642-30658.

[35]KOSKINAS JS, DEUTSCH M, ADAMIDI S, et al.The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients.A real life experience from a tertiary center[J].Eur J Intern Med, 2014, 25 (8) :768-771.

[36]PIPILI C, CHOLONGITAS E, PAPATHEODORIDIS G.Review article:Nucleos (t) ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J].Aliment Pharmacol Ther, 2014, 39 (1) :35-46.

[37]WANG Y, ZHANG C, LI HY, et al.The influence of entecavir on renal function during long-term nucleotide therapy in patients with chronic hepatitis B[J].J Clin Exp Med, 2017, 16 (15) :1502-1505. (in Chinese) 王宇, 张程, 李红艺, 等.恩替卡韦长期抗病毒治疗慢性乙型肝炎对患者肾脏功能的影响[J].临床和实验医学杂志, 2017, 16 (15) :1502-1505.

施引文献

资源附件(0)

访问统计